Table 2.
Infection Classification, Microbiology and Prior Antibiotic Use
| Infection Classification | no./No. (%) |
|---|---|
| Skin and soft tissue | 401/440 (91.1) |
| Cellulitis | 270/401 (67.3) |
| Wound | 67/401 (16.7) |
| Abscess | 64/401 (16.0) |
| Bacteremia | 7/440 (1.6) |
| Primary | 5/7 (71.4) |
| Secondary to SSTI | 2/7 (28.6) |
| Other | 32/440 (7.3) |
| Osteomyelitis | 18/32 (56.3) |
| Septic arthritis/synovitis | 4/32 (12.5) |
| Prosthetic joint infection | 3/32 (9.4) |
| Infected bursa | 3/32 (9.4) |
| Catheter exit site | 1/32 (3.1) |
| Maxillary sinus infection | 1/32 (3.1) |
| Hardware, posterior lumbar tissue | 1/32 (3.1) |
| Lymphadenitis | 1/32 (3.1) |
| Gram-positive cultures | 146/440 (33.2) |
| Staphylococcus aureus | 108/146 (74.0) |
| MRSA | 64/108 (59.3) |
| MSSA | 44/108 (40.7) |
| Streptococci (groups A, B, viridans) | 15/146 (10.3) |
| Prior antibiotic therapya | 314/440 (71.4) |
| Cephalosporinsb | 154/314 (48.9) |
| Vancomycin | 153/314 (48.7) |
| Trimethoprim/sulfamethoxazole | 67/314 (21.3) |
| Clindamycin | 59/314 (18.8) |
Abbreviations: MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; SSTI, skin and soft tissue infection.
aIn CHROME, receipt of at least 1 systemic antibiotic (nonoritavancin) related to the index infection within 30 days before the first dose of oritavancin.
bCephalosporins included the following, in no specific order of frequency: ceftriaxone, cefepime/ceftazidime, cefazolin, ceftaroline, cephalexin/cefadroxil, cefuroxime, cefpodoxime.